Novo Nordisk A/S (NYSE:NVO) Trading Down 1.7% – Should You Sell?

Shares of Novo Nordisk A/S (NYSE:NVO) fell 1.7% on Thursday . The company traded as low as $58.80 and last traded at $59.30. 15,753,189 shares traded hands during trading, a decline of 31% from the average session volume of 22,934,711 shares. The stock had previously closed at $60.33.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on NVO shares. HSBC reaffirmed a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Friday, January 9th. Hsbc Global Res cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $57.79.

Novo Nordisk A/S Trading Down 1.7%

The business has a 50-day moving average price of $52.97 and a two-hundred day moving average price of $54.54. The stock has a market capitalization of $264.77 billion, a P/E ratio of 17.24 and a beta of 0.66. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion for the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several large investors have recently made changes to their positions in the company. Lockheed Martin Investment Management Co. grew its stake in Novo Nordisk A/S by 179.4% during the second quarter. Lockheed Martin Investment Management Co. now owns 43,450 shares of the company’s stock valued at $2,999,000 after acquiring an additional 27,900 shares in the last quarter. Martin Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 53.8% in the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after purchasing an additional 41,129 shares during the period. Cantor Fitzgerald Investment Advisors L.P. bought a new position in Novo Nordisk A/S in the 3rd quarter valued at $1,294,000. Guild Investment Management Inc. grew its position in shares of Novo Nordisk A/S by 20.7% during the 2nd quarter. Guild Investment Management Inc. now owns 36,995 shares of the company’s stock valued at $2,553,000 after purchasing an additional 6,345 shares in the last quarter. Finally, Markel Group Inc. increased its holdings in shares of Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock worth $131,436,000 after purchasing an additional 110,061 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.